Boston Millennia Partners — Full Portfolio
5 tracked investments · listed companies and verified rows first
Clemmons, US
Nate Peaty(Executive Officer, Director)Adam Orsborn(Executive Officer, Director)
Board seatRen Roome· per SEC Form D · $2.5M raise · filed Oct 2025
HealthtechNew York, US
Stuart Goldberg(Executive Officer)Andrew Pecora(Director)Andrew L. Pecora(Executive Officer, Director)Eric Schultz(Executive Officer, Director)Elizabeth Rushforth(Executive Officer)Thomas Gallucci(Executive Officer)
Board seatDana Callow, Jr.· per SEC Form D · $40M raise · filed Feb 2018
Co-investorsEssex Woodlands Healthcare Partners
Korio is a clinical technology company offering a randomization and trial supply management (RTSM/IRT) platform for trial sponsors.
Doylestown, US
Ryan Keane(Executive Officer, Director)Chuck Harris(Executive Officer, Director)
BoardAustin Poole(Director)Hugh R. Roome(Director)B. Bobby Bahram(Director)
Co-investorsBIP VenturesExcelerate Health Ventures
S2N Health provides commercial intelligence, analytics, and go-to-market strategy services for medtech, diagnostics, digital health, and drug delivery companies, from startups to global enterprises.
AI & Machine LearningHealthtechMedical DevicesSales TechBoston, US
Amy Siegel(CEO & Co-Founder)inTim Kofol(CTO & Co-Founder)inTimothy Kofol(Executive Officer, Director)Leah Shea(Chief Product Officer)in
BoardRoome Hugh(Director)Andrew Schwab(Director)in
Co-investorsExcelerate Health VenturesRittenhouse VenturesRobin Hood Ventures
Xevant offers an automated data analytics and reporting platform for pharmacy benefit organizations, using AI to standardize diverse data formats, analyze pharmacy claims, and generate reports and repricing outputs.
AI & Machine LearningDigital HealthSaaSLehi, US
BRANDON NEWMAN(Executive Officer, Director)Brandon Newman(CEO)PETE TANTILLO(Executive Officer)JEFF LININGER(Executive Officer)DANIEL TELFORD(Executive Officer)DON DEGOYLER(Director)
Co-investorsHCAP PartnersTech Council VenturesMartinson VenturesTCV
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.